U.S. Government Cancels Funding Deal for Moderna’s Bird Flu Vaccine

The U.S. Department of Health and Human Services (HHS) has officially terminated a high-profile contract with pharmaceutical company Moderna, halting the late-stage development of its experimental bird flu vaccine.

The canceled agreement, initially worth over $700 million, was aimed at supporting the final development and supply of mRNA-1018—Moderna’s vaccine candidate designed to protect humans from strains of avian influenza, such as H5N1. This decision has surprised many, especially given the growing global concern over the spread of bird flu.

Despite promising early trial results showing strong immune responses in healthy volunteers, federal health officials decided to pull funding, reportedly influenced by internal policy shifts and skepticism regarding mRNA vaccines. The vaccine was part of broader efforts to prepare for a potential flu pandemic.

Health experts are voicing concerns about the cancellation, especially with recent cases of H5N1 infections in the U.S., including one fatality. Scientists warn that further mutation of the virus could lead to a more serious public health crisis if not monitored and managed effectively.

Moderna, in response, expressed disappointment but remains committed to advancing the vaccine through other partnerships and funding opportunities. The company highlighted the importance of pandemic preparedness and reaffirmed its focus on developing life-saving solutions through mRNA technology.